Role of the capsule and the O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing
- 1 December 1983
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 42 (3) , 907-913
- https://doi.org/10.1128/iai.42.3.907-913.1983
Abstract
Epidemiological data show that O18:K1 Escherichia coli is a common cause of neonatal bacteremia and meningitis. These bacteria were capable of multiplying in the bloodstream of newborn rats and were resistant to the bactericidal effects of complement in the absence of specific antibodies. The roles played by the O antigen and the K antigen in complement resistance were analyzed by comparing the bactericidal effects of normal sera and of sera deficient in various complement components or in immunoglobulins. These sera were tested on O18:K1 bacteria and on mutants lacking either the lipopolysaccharide O antigen or the K1 capsular polysaccharide. In addition, O1:K1 cells, which can cause pyelonephritis but which are rare in newborn meningitis and which do not multiply in the bloodstream of newborn rats, were also examined. Different mechanisms of protection against the alternative and classical pathways were recognized: K1-positive cells were resistant to the bactericidal activity of sera deficient in classical complement pathway components, whereas K1-negative cells were sensitive to these sera. Based on these results and on those from complement fixation assays, the K1 sialic acid polysaccharide impedes the activation of, and thus protects the bacteria against, the alternative complement pathway. Not only the K1-negative mutant cells but also O1:K1 bacteria and mutants lacking the O18 oligosaccharide repeating units of the lipopolysaccharide were sensitive to the classical complement pathway. These bactericidal effects were observed even in the absence of specific antibodies. It is proposed that both the K1 capsule and the O18 oligosaccharide restrict antibody-independent classical pathway activation by shielding deeper structures on the cell membrane that are capable of activating this pathway.This publication has 25 references indexed in Scilit:
- Restriction of alternative complement pathway activation by sialosylglycolipidsNature, 1982
- Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membraneThe Journal of Experimental Medicine, 1982
- Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from salmonella minnesota S218 without causing bacterial deathThe Journal of Experimental Medicine, 1982
- Sepsis NeonatorumNew England Journal of Medicine, 1981
- The Association of the O18, K1 and H7 Antigens and the CoIV Plasmid of a Strain of Escherichia coli with its Virulence and ImmunogenicityMicrobiology, 1980
- Transfer of Humoral Secretory and Cellular Immunity from Mother to OffspringPublished by Springer Nature ,1979
- Complement C3 convertase: Cell surface restriction of β1H control and generation of restriction on neuraminidase-treated cellsProceedings of the National Academy of Sciences, 1978
- Escherichia coliK1 Capsular Polysaccharide Associated with Neonatal MeningitisNew England Journal of Medicine, 1974
- PROPERDIN FACTOR D: CHARACTERIZATION OF ITS ACTIVE SITE AND ISOLATION OF THE PRECURSOR FORMThe Journal of Experimental Medicine, 1974
- The bactericidal effect of normal human serum on e. coli strains from normals and from patients with urinary tract infectionsInfection, 1973